Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

NCT04371666 is registered in ClinicalTrials.gov with Kyntra Bio as lead sponsor.

NCT NCT04371666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04371666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Lead sponsor
Kyntra Bio
Phase
Phase 3
Overall status
Terminated
Start date
August 10, 2020
Completion date
August 17, 2023
Enrollment
98 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy